Emyria Ltd · ASX:EMD
Emyria — Investor Presentation (October 2022)
32 slides from Emyria's investor presentation, Oct 13, 2022
Slide 1: MDMA-Inspired Drug Discovery
emyria (ASX:EMD) For personal use only MDMA-Inspired Drug Discovery Developing novel medicines for neuropsychiatric conditions, inspired by MDMA 13 Oct 2022 | Webinar Dr Michael Winlo (Emyria) Prof Matt Piggott (UWA) 1
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. T
Slide 3: MDMA-Inspired Drug Discovery | Emyria & UWA agenda
MDMA-INSPIRED DRUG DISCOVERY | EMYRIA & UWA For personal use only Introduction to Emyria 4 The growing interest in psychedelic-assisted therapy 8 What is MDMA? 13 MDMA’s therapeutic potential 15 MDMA-inspired drug discovery 17 Case Study: UWA-121 20 Michael Matt Progress to date and next steps 22 Wi
Slide 4: A clinical stage biotech focused on unmet needs in neuroscience and mental health
For personal use only A clinical stage biotech, informed by patient experience, focused on unmet needs in neuroscience and mental health 4
Slide 5: Clinical focus, leading programs and comparative advantages
CLINICAL Neuroscience and mental health FOCUS For personal use only LEADING CLINICAL: ULTRA-PURE CANNABINOID MEDICINES PROGRAMS ● Emyria’s proprietary “RX” platform improves the bioavailability, & TRACTION release profile, safety & tolerability of cannabinoid-based medicines ● Supports multiple globa
Slide 6: Emyria Investment Highlights
EMYRIA | INVESTMENT HIGHLIGHTS Ultra-Pure cannabinoid For personal use only 1 formulation technology, 2 Advanced clinical programs 3 Dose response insights from Real World Data (RWD) partnership ready Demonstrated benefits over incumbent EMD-RX5: In pivotal Phase 3 clinical Emyria’s clinical service,
Slide 7: Vision
| VISION For personal use only Accelerate the development of promising treatments where evidence is lacking BY COLLABORATING WITH : PATIENTS to generate GLOBAL EXPERTS to create CLINICAL DATA & NEW TREATMENTS (formulations & analogues) Continue expanding our well advanced proprietary cannabinoid Dru
Slide 8: The growing interest in psychedelic-assisted therapy
THE GROWING INTEREST IN MDMA-INSPIRED For personal use only PSYCHEDELIC DRUG DISCOVERY ASSISTED THERAPY 8
Slide 9: Mental health disorders affect millions globally
MENTAL HEALTH DISORDERS “Affects 1 in 4 People, Globally ” For personal use only POST-TRAUMATIC STRESS MAJOR DEPRESSION DISORDER (PTSD) 264 2 in 3 million Veterans suffer from PTSD People suffer depression globally 20-30% of PTSD sufferers show some 40-60% show some response to pharmacotherapy respo
Slide 10: Psychedelic-assisted therapy: what is it?
PSYCHEDELIC-ASSISTED THERAPY | WHAT IS IT? For personal use only Psychedelics alter communication between brain networks, such as the Default Mode Network (DMN), which are associated with many mental illnesses. Thought to enable patients to break out of rigid styles of thinking, feeling and behaving
Slide 11: Novel psychedelic medicine development is attracting major investment globally
$ NOVEL PSYCHEDELIC MEDICINE DEVELOPMENT $100b IS ATTRACTING MAJOR INVESTMENT GLOBALLY Estimated market for psychedelic medicines For personal use only MARKET CAP COMPANY PROGRAMS + FOCUS ($AUD) RELMADA Esmethadone (NMDAR antagonist), psilocybin (5HT2A) and esmethadone $1,600M THERAPEUTICS derivativ
Slide 12: What is MDMA?
For personal use only WHAT IS MDMA ? 12
Slide 13: What is MDMA?
WHAT IS MDMA? For personal use only MDMA (3,4-methylenedioxymethamphetamine or “ecstasy”) - an amphetamine that causes release of 3 neurotransmitters: Serotonin Dopamine Noradrenaline contributes to mood, associated with reward, stimulant activity, prosocial effects euphoria attention MDMA is the be
Slide 14: Unique psychopharmacological effects of MDMA
UNIQUE PSYCHOPHARMACOLOGICAL EFFECTS OF MDMA For personal use only ● feelings of wellbeing ● sociability and extroversion ● interpersonal trust INCREASED AN ALERT BUT ALTERED STATE OF CONSCIOUSNESS DECREASED ● feelings of fear & defensiveness These effects suggest MDMA could be a promising adjunct t
Slide 15: Therapeutic applications - MDMA-assisted therapy for PTSD
THERAPEUTIC APPLICATIONS - MDMA-ASSISTED THERAPY FOR PTSD For personal use only 67% Of participants in the MDMA group lost their PTSD diagnosis following treatment, compared to 32% in the therapy-only group. In a landmark Phase 3 study (n = 91) [1], patients with PTSD were randomized to receive MDMA
Slide 16: Drug discovery with UWA
MDMA-INSPIRED For personal use only DRUG DISCOVERY with | commercial in confidence | Emyria 2022 16
Slide 17: Drug Discovery: new drug development opportunities with MDMA analogues
MDMA-INSPIRED DRUG DISCOVERY “Emyria is creating new chemical entities with the NEW DRUG DEVELOPMENT potential to become neuropsychiatric treatments” For personal use only WHY INNOVATION OPPORTUNITIES MDMA? WITH MDMA-ANALOGUES Privileged chemistry Adjust metabolism? ● Small, stable, brain-penetratin
Slide 18: Drug Discovery Workflow
MDMA-INSPIRED DRUG DISCOVERY | WORKFLOW NEW DRUG DEVELOPMENT For personal use only Take MDMA Design and synthesise Screen analogues Prioritise as inspiration new compounds (In vitro and In vivo) indications Next-gen MDMA ● Pharmacology (target) screens Neuropsychiatric ● Safety screens treatments Pr
Slide 19: Case Study: UWA-121, an MDMA-analogue for Parkinson's disease
CASE STUDY: UWA-121, an MDMA-analogue for Parkinson’s disease NEW DRUG DEVELOPMENT For personal use only Background Video + Profound improvement Small series of MDMA analogues evaluated in rat and primate models Single enantiomer of PD therapy (mirror image) most promising ー Psychoactivity unsuitabl
Slide 20: The UWA Team
THE UWA TEAM For personal use only Dr Joelie Loh Adam Fielding Dr Glenn Pullella Analytical chemistry Data curation (Honours student) Design & Synthesis | commercial in confidence | Emyria 2022 20
Slide 21: Progress and next steps
PROGRESS MDMA-INSPIRED For personal use only DRUG AND DISCOVERY NEXT STEPS with 21
Slide 22: Drug Discovery: Progress to date
MDMA-INSPIRED DRUG DISCOVERY | PROGRESS TO DATE with NEW DRUG DISCOVERY For personal use only THE MDMA ANALOGUE LIBRARY ● >140 unique MDMA analogues -created and characterised ● Ongoing synthesis and screening [1] (grew 40% since partnership) ● Very few with “off-target” effects LIBRARY EXCLUSIVELY
Slide 23: Potential of new treatments
MDMA-INSPIRED DRUG DISCOVERY | POTENTIAL OF NEW TREATMENTS For personal use only THERAPEUTIC CLASS RECEPTOR ACTION COMMERCIALISED EXAMPLES MARKET SIZING ($US) 5HT2B Antagonism No approved selective 5HT2B antagonists Fibrosis antagonists of 5HT2B One company developing drugs for Sales of Esbriet = $1
Slide 24: Promising early results
MDMA-INSPIRED DRUG DISCOVERY | PROMISING EARLY RESULTS For personal use only # EMYRIA COMPOUNDS THAT THERAPEUTIC CLASS RECEPTOR ACTION DEMONSTRATE RECEPTOR ACTION 5HT2B antagonists Antagonism of 5HT2B Several More selective for Dopamine reuptake inhibition (DRI) Several DAT > NET or SERT More select
Slide 25: Screening workflow
MDMA-INSPIRED DRUG DISCOVERY | SCREENING WORKFLOW Therapeutic Grouping For personal use only Potent MDMA Broad neurological Synthesis & screening action with potential to engine become “next-gen” psychedelic-assisted therapies ~140 compounds to date [1] MDMA Selective Analogue Synthesis Screening DA
Slide 26: Preclinical workflow
MDMA-INSPIRED DRUG DISCOVERY | PRECLINICAL WORKFLOW Therapeutic Grouping Phenotypic Screening For personal use only Potent MDMA Broad neurological Synthesis & screening action with potential to engine become “next-gen” psychedelic-assisted therapies Preclinical screens ~140 compounds (behavioural ev
Slide 27: Preclinical workflow
MDMA-INSPIRED DRUG DISCOVERY | PRECLINICAL WORKFLOW Therapeutic Grouping Phenotypic Screening For personal use only Potent MDMA Broad neurological Synthesis & screening action with potential to engine become “next-gen” psychedelic-assisted therapies Preclinical screens ~140 compounds Behavioural (be
Slide 28: Advanced preclinical screening | SmartCube
ADVANCED PRECLINICAL SCREENING | SMARTCUBE(R) - computer vision and AI For personal use only SmartCube® is an automated testing platform that presents a sequence of challenges to a mouse and incorporates computer vision and AI to process and analyze more than half a million data points per mouse per
Slide 29: What's next?
MDMA-INSPIRED DRUG DISCOVERY | WHAT’S NEXT? NEW DRUG DISCOVERY BACKED BY UWA RESEARCH For personal use only IN THE NEXT 12 MONTHS, EMYRIA INTENDS TO: ● Deliver results from multiple preclinical programs on select MDMA analogues ● Select leads by proof-of-concept efficacy studies in animal models ● Ex
Slide 30: Drug Discovery Summary
MDMA-INSPIRED DRUG DISCOVERY | SUMMARY NEW DRUG DISCOVERY BACKED BY UWA RESEARCH For personal use only Emyria-UWA MDMA analogue library captures a unique chemical space with differentiated pharmacology ● Largest reported database of MDMA derivatives currently in development with >140 compounds in th
Slide 31: Questions & Answers
For personal use only Questions & Answers 31
Slide 32: Contact Information
For personal use only CONTACT INFORMATION Michael Winlo mwinlo@emyria.com Investors investors@emyria.com Media media@emyria.com General info@emyria.com 32